This may suggest that the reductions seen from GLP-1s in both depression and anxiety are a direct effect, not subsequent to weight loss
For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions
We had the question, Would that translate in potentially impacting their cancer risks? George adds that the study had several limitations and that the data showed that older adults on GLP-1s experienced fewer benefits against cancer than middle-aged and younger patients
I'm able to eat reduced, healthy portions without constantly feeling hungry
